Voloridge Investment Management LLC Has $12.89 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

Voloridge Investment Management LLC reduced its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 56.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 196,661 shares of the company's stock after selling 251,756 shares during the period. Voloridge Investment Management LLC's holdings in AstraZeneca were worth $12,885,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Banque Transatlantique SA bought a new position in AstraZeneca during the fourth quarter worth about $26,000. CoreCap Advisors LLC raised its position in AstraZeneca by 31.8% in the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock worth $42,000 after purchasing an additional 155 shares during the last quarter. Crews Bank & Trust bought a new position in AstraZeneca in the fourth quarter valued at approximately $55,000. Golden State Wealth Management LLC bought a new position in AstraZeneca in the fourth quarter valued at approximately $55,000. Finally, Newbridge Financial Services Group Inc. bought a new position in shares of AstraZeneca during the fourth quarter worth $55,000. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Performance

Shares of AstraZeneca stock traded up $0.05 during trading on Thursday, hitting $70.43. 1,522,818 shares of the stock were exchanged, compared to its average volume of 5,165,529. The stock has a market capitalization of $218.43 billion, a price-to-earnings ratio of 31.13, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40. The company has a fifty day moving average price of $69.45 and a 200-day moving average price of $69.58. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. The firm had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.06 EPS. As a group, equities analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AZN has been the topic of a number of recent analyst reports. UBS Group raised shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price objective on the stock. Finally, Morgan Stanley started coverage on shares of AstraZeneca in a research note on Wednesday, February 12th. They issued an "overweight" rating on the stock. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, AstraZeneca presently has an average rating of "Buy" and a consensus price target of $88.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.